1.86

0.54% 0.01

After Hours: 1.86

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $1.86, with a volume of 2.49M. It is up +0.54% in the last 24 hours and up +39.85% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Previous Close:

$1.85

Open:

$1.85

24h Volume:

2.49M

Relative Volume:

1.46

Market Cap:

$391.14M

Revenue:

$194.75M

Net Income/Loss:

$-51.26M

P/E Ratio:

-3.5769

EPS:

-0.52

Net Cash Flow:

$-23.38M

1W Performance:

+8.77%

1M Performance:

+39.85%

6M Performance:

+35.77%

1Y Performance:

+96.85%

1-Day Range:

$1.78

$1.86

1-Week Range:

$1.63

$1.86

52-Week Range:

$0.80

$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1182)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

167

Twitter

@akebiatx

Next Earnings Date

2024-11-07

Latest SEC Filings

AKBA's Discussions on Twitter

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

06:59 AM

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard

Nov 01, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com

Nov 01, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz

Nov 01, 2024

Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World

Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat

Oct 31, 2024

Oct 25, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 25, 2024

Oct 23, 2024

Akebia stock climbs 8% on dialysis provider supply agreement - MSN

Oct 23, 2024

High Growth Tech Stocks to Watch in October 2024 - Simply Wall St

Oct 23, 2024

Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St

Oct 23, 2024

Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia

Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract - Investing.com

Oct 22, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Oct 22, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance

Oct 22, 2024

Oct 17, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne

Oct 17, 2024

Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com

Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK

Oct 16, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Oct 16, 2024

Oct 15, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan

Oct 15, 2024

Oct 14, 2024

A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News

Oct 14, 2024

Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily

Oct 14, 2024

Oct 12, 2024

Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada

Oct 12, 2024

Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat

Oct 12, 2024

Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India

Oct 12, 2024

Oct 11, 2024

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - Lelezard

Oct 11, 2024

Oct 10, 2024